Research course


University of Nottingham · School of Medicine
PhDMSc by researchMPhil

Entry requirements

Candidates who wish to register for a PhD will be required to possess a first degree with at least 2:1 (or international equivalent) classification; candidates who wish to register for a DM will require a registrable medical qualification. Evidence of research activity, including BMedSci or BSc degrees, will be an advantage; candidates who wish to register for an MRes, MSc (by research) or MPhil degree will be required to possess a first degree with at least 2:2 (or international equivalent) classification.

Months of entry

December, October, July, April, February

Course content

Acute myeloid leukaemia (AML) affects the myeloid-producing cells in the bone marrow. It is the most common acute leukaemia to affect adults and its incidence increases with age.

The 5 year overall survival rates of patients with AML in the UK are 44% for patients under 55 years old, and just 13% for patients older than 55 years. A number of different cytotoxic drugs are used to treat AML and there are many new agents in clinical trials. In addition, patients with AML and other haematological disorders, may undergo a haematopoietic stem cell transplants.

The Nottingham Haematology Group, headed by Professor Nigel Russell, encompasses both clinical and laboratory research. The clinical research has a pioneering interest in the development of peripheral blood stem cells for matched and unrelated donor transplantation.

The group has one of the UK’s largest bone marrow transplant (BMT) programmes with participation in national and international clinical trials in BMT and cord blood transplantation. The laboratory research focuses on understanding both the pathogenesis of AML and the chemo-resistance phenotype often seen in the disease.

Areas of particular interest in AML research include the role of the ABC drug transporter protein family, DNA damage and repair mechanisms, telomere maintenance, identification of factors that predispose to AML and understanding contributory factors underpinning minimal residual disease. The research aims to identify ways to maximise the therapeutic efficacy of existing drugs and to evaluate new treatments for AML.

Qualification and course duration


full time
36-48 months
part time
72-96 months

MSc by research

part time
24 months
full time
12 months


part time
48 months
full time
24 months

Course contact details

Postgraduate Enquiries
+44 (0)115 951 5559